
Personalized Dendritic Cell Vaccine Shows 100% 12-Month Survival in Small Glioblastoma Trial
A personalized dendritic cell vaccine called ZSNeo-DC has produced promising early results in patients with newly diagnosed glioblastoma (GBM), the most aggressive form of brain cancer. In a Phase Ib trial published July 4 in Nature Communications, all 11 patients receiving the vaccine were alive at 12 months, and median progression-free survival reached 16.2 months, […]










